Reunion Neuroscience (TSX:REUN) Institutional Ownership : 2.77% (As of Apr. 27, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Reunion Neuroscience's institutional ownership is 2.77%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Reunion Neuroscience's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Reunion Neuroscience's Float Percentage Of Total Shares Outstanding is 84.03%.

Reunion Neuroscience Institutional Ownership Historical Data

The historical data trend for Reunion Neuroscience's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience Institutional Ownership Chart

Reunion Neuroscience Historical Data

The historical data trend for Reunion Neuroscience can be seen below:

	2022-10-31	2022-11-30	2022-12-31	2023-01-31	2023-02-28	2023-03-31	2023-04-30	2023-05-31	2023-06-30	2023-07-31
Institutional Ownership	2.68	2.61	2.57	3.25	3.19	3.08	3.12	3.21	2.46	2.77

Reunion Neuroscience Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Reunion Neuroscience (TSX:REUN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3

Website

https://www.reunionneuro.com

Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.